Compare GT & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | NUVB |
|---|---|---|
| Founded | 1898 | 2018 |
| Country | United States | United States |
| Employees | N/A | 307 |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2005 | N/A |
| Metric | GT | NUVB |
|---|---|---|
| Price | $6.18 | $5.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $9.13 | ★ $11.38 |
| AVG Volume (30 Days) | ★ 8.2M | 4.3M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,280,000,000.00 | N/A |
| Revenue This Year | N/A | $203.82 |
| Revenue Next Year | $3.06 | $58.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.43 | $1.84 |
| 52 Week High | $11.65 | $9.75 |
| Indicator | GT | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 61.24 |
| Support Level | $5.43 | $5.22 |
| Resistance Level | $6.26 | $5.34 |
| Average True Range (ATR) | 0.26 | 0.38 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 45.30 | 72.56 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.